More than 200 abstracts from therapies across the Novartis Oncology portfolio will be presented at two December medical congresses. These will provide new data and profile potential patient benefits from ongoing collaboration with the oncology community.
The American Society of Hematology (ASH) annual meeting which begins 6 December in San Francisco, CA, will feature 34 oral presentations on the Novartis Oncology portfolio, including 20 on Glivec (imatinib), six on Tasigna (nilotinib), five on Exjade (deferasirox) and three on products in development. The CTRC-AACR San Antonio
Breast Cancer Symposium (SABCS), beginning 10 December, will feature four oral presentations, including three on Femara (letrozole) and one on Zometa (zoledronic acid).
“Our robust portfolio and dedication to oncology research is ultimately about providing patients and their physicians with new treatment options to address unmet medical needs,” said David Epstein, CEO and President of Novartis Oncology. “We are pleased that our ongoing work with experts in the fields of oncology and hematology continue to provide valuable new insights across multiple cancer types.”